RT Journal Article
SR Electronic
T1 The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 811
OP 821
DO 10.20892/j.issn.2095-3941.2019.0209
VO 16
IS 4
A1 Wu, Jianghua
A1 Sun, Wei
A1 Wang, Haiyue
A1 Huang, Xiaozheng
A1 Wang, Xinyu
A1 Jiang, Weiyang
A1 Jia, Ling
A1 Wang, Ping
A1 Feng, Qin
A1 Lin, Dongmei
YR 2019
UL http://www.cancerbiomed.org/content/16/4/811.abstract
AB Objective To investigate the correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma (LADC) patients.Methods We reviewed 428 consecutive, surgically resected cases of LADC from October 2015 to December 2016 from our center. PD-L1 expression was evaluated based on tumor proportion score (TPS). Correlation and co-occurrence of PD-L1 expression level with those of classical driver genes, such as EGFR, ALK, ROS-1, and KRAS and with clinical variables and disease-free survival (DFS) were analyzed.Results Seventy of the 428 cases (16.4%) showed TPS = 1%, and 21 cases (4.9%) showed TPS = 50%. PD-L1 positive expression was significantly associated with male gender, smoking, advanced TNM stage, and solid histologic subtype. Both TPS = 1% and = 50% were correlated with the absence of an EGFR mutation (P < 0.001) and the presence of ALK rearrangement ( P = 0.024). KRAS mutation was associated with TPS = 50% (P = 0.035). PD-L1 positivity commonly overlapped with the alterations of classical driver oncogenes (58.5% with TPS = 1% and 42.9% with TPS = 50%). Approximately three-quarters of PD-L1 positive cases co-occurred with classical therapeutic-gene aberrations in cases with stage III/IV cancer or cancer progression. LADC could be divided into four subgroups based on the expression profile of current routine biomarkers for potential therapeutic strategies.Conclusions PD-L1 expression is not only closely correlated with classic gene alterations but also commonly overlaps with the aberrations of classical driver oncogenes in Chinese LADC patients. These findings provide a useful overview of clinical strategies that rely on the profile of routinely used molecular biomarkers.